

maps of the SC and classic FEF are different, and only few FEF cells encode ipsilateral saccades [8] (with an unknown motor map). Possible further support for this argument is that SE had spared FEFs and weak probe effects.

A brief current pulse to the superficial layer of the rat SC produces a prolonged (~300 ms) burst of excitatory postsynaptic current in intermediate layer cells [10]. An additional input to the deeper layers could trigger a saccade. By extension, a visual stimulus in the blind hemifield of our patients could not, on its own, trigger a goal-directed saccade, presumably because motor activity in the intermediate layers of the ipsilesional SC (SCi) is absent. Thus, we hypothesize, mostly for DR, that probe-evoked activity in retino-tectal afferents to the SCi's superficial layers descended to intermediate layers and enhanced weak motor preparatory activity for contralateral anti-saccades, itself due to a crossed descending motor signal from contralateral FEF-to-SCi [4,8]. The many and varied residual abilities among blindsight patients suggest that blindsight relies on more than one residual pathway. Here we provide evidence indicating that the mammalian homologue of the primitive reptilian retino-tecto-reticular pathway is remarkably functional in humans, thus permitting a form of 'action' blindsight [1].

SUPPLEMENTAL INFORMATION

Supplemental information includes experimental procedures, and one figure and can be found with this article online at <https://doi.org/10.1016/j.cub.2018.09.006>.

ACKNOWLEDGEMENTS

This work was supported by the Canadian Institutes of Health Research (CIHR) and Natural Science and Engineering Research Council (NSERC). We thank our two very special hemispherectomy patients (DR and SE) for accepting to participate in these long experiments.

AUTHOR CONTRIBUTIONS

Conceptualization, Methodology, Software, Formal Analysis and Writing-Review

and Editing, O.S., D.G.; Investigation, O.S.; Writing-Original Draft, O.S., D.G.; Supervision, D.G.; Funding Acquisition, D.G.

REFERENCES

1. Danckert, J., and Rossetti, Y. (2005). Blindsight in action: what can the different subtypes of blindsight tell us about the control of visually guided actions? *Neurosci. Biobehav. Rev.* 29, 1035–1046.
2. Ottes, F.P., Van Gisbergen, J.A., and Eggermont, J.J. (1986). Visuomotor fields of the superior colliculus: a quantitative model. *Vision Res.* 26, 857–873.
3. Georgy, L., Celeghin, A., Marzi, C.A., Tamietto, M., and Ptito, A. (2016). The superior colliculus is sensitive to gestalt-like stimulus configuration in hemispherectomy patients. *Cortex* 81, 151–161.
4. Leh, S.E., Johansen-Berg, H., and Ptito, A. (2006). Unconscious vision: New insights into the neuronal correlate of blindsight using diffusion tractography. *Brain* 129, 1822–1832.
5. Savina, O., Bergeron, A., and Guitton, D. (2013). Blindsight after hemidecortication: visual stimuli in blind hemifield influence anti-saccades directed there. *Cortex* 49, 861–876.
6. Dorris, M.C., Olivier, E., and Munoz, D.P. (2007). Competitive integration of visual and preparatory signals in the superior colliculus during saccade programming. *J. Neurosci.* 27, 5053–5062.
7. Munoz, D.P., and Wurtz, R.H. (1995). Saccade-related activity in monkey superior colliculus. II. Spread of activity during saccades. *J. Neurophysiol.* 73, 2313–2333.
8. Crapse, T.B., and Sommer, M.A. (2009). Frontal eye field neurons with spatial representations predicted by their subcortical input. *J. Neurosci.* 29, 5308–5318.
9. Kato, R., Takaura, K., Ikeda T., Yoshida, M., and Isa, T. (2011). Contribution of the retino-tectal pathway to visually guided saccades after lesion of the primary visual cortex in monkeys. *Eur. J. Neurosci.* 33, 1952–1960.
10. Özen, G.J., Augustine, G.J., and Hall, W.C. (2000). Contribution of superior colliculus layer neuron to premotor bursts in the superior colliculus. *J. Neurophysiol.* 84, 460–471.

¹Montreal Neurological Institute and Department of Neurology and Neurosurgery, McGill University, Montreal, H3A2B4, Canada. ²Psychology Department, McGill University, Montreal, H3A2B4, Canada. *E-mail: daniel.guitton@mcgill.ca

The editors of Current Biology welcome correspondence on any article in the journal, but reserve the right to reduce the length of any letter to be published. All Correspondence containing data or scientific argument will be refereed. Queries about articles for consideration in this format should be sent by e-mail to cbiol@current-biology.com

Correspondence

Continued need for non-human primate neuroscience research

Anna S. Mitchell¹, Alexander Thiele², Christopher I. Petkov², Angela Roberts³, Trevor W. Robbins³, Wolfram Schultz⁴, and Roger Lemon^{5,*}

Neuroscience research in non-human primates (NHPs) has delivered fundamental knowledge about human brain function as well as some valuable therapies that have improved the lives of human patients with a variety of brain disorders. Research using NHPs, although it is facing serious challenges, continues to complement studies in human volunteers and patients, and will continue to be needed as the burdens of mental health problems and neurodegenerative diseases increase. At the same time, research into the 3Rs is helping to ameliorate the harms experienced by NHPs in experimental procedures, allowing the effective combination of optimal welfare conditions for the NHPs and high quality research.

We write as a group of UK scientists committed to neuroscience research in NHPs at a critical point in the debate over their use in research. Our commitment stems from the notable advances that this research has already achieved, and because of our awareness that the monkey represents the best available model for our understanding of the human brain. Last year, the EU SCHEER report [1] highlighted key research areas where NHPs were still needed. These included testing of new drugs, infectious diseases (including Ebola, Zika and TB), and neuroscience. The need to alleviate the modern burdens of human neurodegenerative diseases and mental health disorders represents one of the most powerful arguments for sustaining primate research. This research now engages modern molecular, electrophysiological, behavioural and



imaging technologies to identify the underlying mechanisms of disease, and some of it will lead to successful treatments.

We emphasise that NHP studies, using invasive methods, complement those in human volunteers and patients, using non-invasive methods such as brain imaging and computational modelling. For example, the Brain Prize in 2017 was awarded to three scientists in the UK who, respectively, discovered the neuronal mechanism of reward in monkeys, modelled this reward mechanism, and tested these models in human volunteers using fMRI [2]. Recent analysis shows that scientists who use NHPs in their research are also very active in using non-animal approaches to address current problems in basic and translational neuroscience [3]. NHP scientists also contribute to advances in welfare and the 3Rs [3].

Similarly, close interaction between human and monkey studies was also vital to the development of the parkinsonian model in the macaque which led to the discovery that deep brain stimulation of a tiny brain structure, the subthalamic nucleus, was an effective therapy for the motor disorders associated with Parkinson's disease, research that was recognised by the Lasker Award in 2014 [4]. Over 250,000 Parkinson patients worldwide have since benefited from this treatment. Recent developments that have come directly from monkey research include the use of brain-machine interfaces for restoring movement to paralysed patients, new therapies for stroke patients with poor hand function, new strategies to harness brain plasticity to compensate for perceptual and cognitive impairment, and a better understanding of symptoms underlying psychiatric disorders as well as cognitive functioning in the healthy brain.

UK and EU animal research legislation requires a 'harm-benefit' analysis to determine whether the harms involved in the research are justified by advances in fundamental science or medical benefits that might result from the study. Therefore, in addition to assessing the benefits of NHP research, there has been

an increased focus on reducing harms and understanding the overall level of severity experienced by research animals. This is of particular significance for NHPs in long-term neuroscience studies involving complex behavioural tasks.

Government regulators in the UK, and in some other EU countries, *prospectively* assess all such research as 'severe' because of the *potential* to cause severe harm. Critically, accumulating evidence shows that the lifetime experience of a great majority of the monkeys used in academic research in the UK is not severe, but is actually 'moderate'. Starting in 2013, annual retrospective reviews of the *actual* severity experienced by each monkey in neuroscience research procedures has revealed that only 1% of the 366 monkeys used (New World marmosets and Old World macaques) actually experienced severe harms (as defined by the EU Directive 2013/63/), while most (66%) experienced moderate harms, or less (26% 'mild' and 7% 'non-recovery'). These results are consistent with the broader set of United Kingdom Home Office statistics for basic research using NHPs over the same period (3% of severe procedures for the years 2013–2016). They also confirm the moderate level of harms that was first reported by the Home Office Pickard Report in 2013 [5]. This key distinction between the potential to cause severe harm and the actual level of severity is crucial but is often lost or misunderstood in discussions amongst the general public.

We are seriously concerned about calls to UK and other EU government regulators for a ban on all research involving NHPs, as well as in many other species, which has a prospective rating of severe. Such a ban would prevent disease-related medical and neuroscience research, damaging both fundamental and translational science. We have identified two serious consequences that such a ban would cause to NHP neuroscientific research; many more exist and will develop, impacting the wider scientific community, the welfare of non-human species, and human health.

First, it would ban most of the basic, fundamental neuroscience

research, essential for understanding complex cognition and other processes that occur in the primate brain. We stress that the ban would result from the current situation in which most NHP neuroscience research is currently prospectively banded severe by government regulators, although as pointed out above, the great majority of primates used actually experience moderate harms or less.

Second, it would ban any present (or future) study in which a disease model is created in a monkey, indeed necessarily causing severe harms that reflect the impact of the brain disorder (e.g. Parkinson's) in humans. But limited use of such models is still essential to help find effective treatments for a whole range of neurodegenerative and neuropsychiatric conditions that affect millions of humans.

We believe that in the coming period some increase in NHP studies in carefully targeted areas of neuroscience will still be needed. To ban useful primate disease models would be an extremely dangerous step to take, given the urgent need to find treatments for people suffering from these conditions.

REFERENCES

1. Vermeire, T., Epstein, M., Badin, R.A., Flecknell, P.A., Hoet, P., Hudson-Shore, M., *et al.* (2017). https://ec.europa.eu/health/sites/health/files/scientific_committees/scheer/docs/scheer_o_004.pdf
2. The Brain Prize 2017. http://www.thebrainprize.org/flx/prize_winners/previous_prize_winners/prize_winners_2017/
3. Lemon, R.N. (2018). Applying the 3Rs to neuroscience research involving nonhuman primates. *Drug Discov. Today* 23, 1574–1577.
4. LaskerPrize2014. <http://www.laskerfoundation.org/awards/show/deep-brain-stimulation-for-parkinsons-disease/>
5. Pickard, J. (2013). https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/261687/cs_nhp_review_FINAL_2013_corrected.pdf

¹University of Oxford, Department of Experimental Psychology, Oxford OX1 3SR, UK. ²Institute of Neuroscience, Newcastle University Medical School, Newcastle upon Tyne NE2 4HH, UK. ³Department of Psychology, University of Cambridge, Cambridge CB2 3EB, UK. ⁴Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 3EB, UK. ⁵Institute of Neurology, University College London, London WC1N 3BG, UK. *E-mail: r.lemon@ucl.ac.uk